Zealand Pharma’s GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeks
Zealand Pharma is back with updated findings for its GLP-1/GLP-2 receptor dual agonist, finding mean body weight reductions rose to 11.6% for a higher dosing regimen after 28 weeks in a phase 1b trial.
Weight-loss surgery trumps popular Ozempic treatment in shocking new comparison
Weight-loss surgery was shown to be five times more effective than weekly injections of popular GLP-1 receptor agonists, including semaglutide (such as Ozempic) and tirzepatide (such as Mounjaro). The finding comes from a recent study presented this week at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting in Washington. Researchers […]
Compounders lose case over semaglutide shortage
A federal court once again ruled against a trade group for large compounding pharmacies that sought to put Novo Nordisk’s blockbuster obesity drug semaglutide back on the FDA’s shortage list so compounders could continue making …
STAT+: Zealand’s GLP-2 candidate shows early weight loss results
Zealand Pharma said Wednesday that its obesity candidate that uses a unique mechanism led to notable weight loss in an early trial. Over 28 weeks, patients taking dapiglutide, which targets receptors of the GLP-1 and GLP-2 hormone, lost on average 11.6% of their weight, while those on placebo lost 0.2%. The company suggested the results […]
Mark Cuban’s company teams with telehealth firm on obesity drugs
Mark Cuban’s Cost Plus Drug Co. and virtual care provider 9amHealth have partnered to offer obesity medications through a new program targeting self-insured employers. Under the partnership, 9amHealth will use low-cost oral obesity medications sourced from Cost Plus Drugs alongside branded GLP-1 drugs acquired through direct manufacturer deals, according to a June 17 news release […]
Research funding has unexpected benefits. A lizard study led to Ozempic
In a new weekly video series, STAT’s @HoganAlex examines the stakes of ongoing court battles over NIH grant funding.
Bariatric surgery better than GLP-1 drugs for weight loss : ASMBS study
Post Content
Blind Spots: Comparing the Vision Costs of Weight-Loss Drugs
Although GLP-1 drugs make headlines for vision risks, other weight-loss medications carry their own eye-related side effects. Medscape Medical News
Blockbuster Weight-Loss Drugs Linked to Massive Spike in Depression, Anxiety, and Suicidal Behavior
Groundbreaking study of over 160,000 patients reveals GLP-1 drugs like Ozempic and Wegovy nearly double the risk of psychiatric disorders, with some patients showing a shocking 195% increase in major depression. While millions celebrate dramatic weight loss from trendy GLP-1 agonist drugs like Ozempic and Wegovy, a recent study has uncovered a dark side that […]
The Overlooked Connection Between GLP-1s, Obesity, and Eating Disorders
Gretchen Zimmermann, MBA, RD, VP of Clinical Strategy at Vida Health The false belief that people with obesity do not have eating disorders is one of the most harmful misconceptions in obesity care. In reality, individuals with obesity are at a high risk for eating disorders. The intersection of obesity, mental health, and disordered eating […]